Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

The impact of body size changes on recurrence risk depends on age and estrogen receptor status in primary breast cancer.

Tryggvadottir H, Ygland Rödström M, Markkula A, Kenéz X, Isaksson K, Borgquist S, Jernström H.

Cancer Causes Control. 2019 Sep 12. doi: 10.1007/s10552-019-01227-6. [Epub ahead of print]

PMID:
31515643
3.

Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients.

Tryggvadottir H, Huzell L, Gustbée E, Simonsson M, Markkula A, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H.

Front Oncol. 2018 Oct 12;8:428. doi: 10.3389/fonc.2018.00428. eCollection 2018.

4.

Patients' reasoning regarding the decision to participate in clinical cancer trials: an interview study.

Dellson P, Nilsson K, Jernström H, Carlsson C.

Trials. 2018 Sep 29;19(1):528. doi: 10.1186/s13063-018-2916-9.

5.

Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment.

Björner S, Rosendahl AH, Tryggvadottir H, Simonsson M, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Front Endocrinol (Lausanne). 2018 Jun 6;9:306. doi: 10.3389/fendo.2018.00306. eCollection 2018.

6.

Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis.

Wisse A, Tryggvadottir H, Simonsson M, Isaksson K, Rose C, Ingvar C, Jernström H.

Cancer Causes Control. 2018 Jul;29(7):643-656. doi: 10.1007/s10552-018-1042-z. Epub 2018 May 26.

7.

Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.

Isfoss BL, Holmqvist B, Sand E, Forsell J, Jernström H, Olsson H.

BMC Cancer. 2018 Feb 27;18(1):230. doi: 10.1186/s12885-018-4151-x.

8.

Current smoking is associated with a larger waist circumference and a more androgenic profile in young healthy women from high-risk breast cancer families.

Ellberg C, Olsson H, Jernström H.

Cancer Causes Control. 2018 Feb;29(2):243-251. doi: 10.1007/s10552-017-0999-3. Epub 2018 Jan 3.

9.

Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.

Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Front Endocrinol (Lausanne). 2017 Nov 28;8:332. doi: 10.3389/fendo.2017.00332. eCollection 2017.

10.

Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.

Elebro K, Bendahl PO, Jernström H, Borgquist S.

Breast Cancer Res Treat. 2017 Oct;165(3):645-657. doi: 10.1007/s10549-017-4343-0. Epub 2017 Jun 22.

11.

Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.

Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Oncotarget. 2017 Feb 7;8(6):9093-9107. doi: 10.18632/oncotarget.14082.

12.

High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients-Results from a Population-Based Breast Cancer Cohort.

Elebro K, Borgquist S, Rosendahl AH, Markkula A, Simonsson M, Jirström K, Rose C, Ingvar C, Jernström H.

Clin Cancer Res. 2017 Feb 1;23(3):766-777. doi: 10.1158/1078-0432.CCR-16-1095. Epub 2016 Nov 3.

13.

The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.

Simonsson M, Björner S, Markkula A, Nodin B, Jirström K, Rose C, Borgquist S, Ingvar C, Jernström H.

Int J Cancer. 2017 Jan 1;140(1):163-175. doi: 10.1002/ijc.30432. Epub 2016 Sep 28.

14.

The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer.

Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H.

Breast Cancer (Dove Med Press). 2016 May 27;8:117-24. doi: 10.2147/BCTT.S106097. eCollection 2016.

15.

Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort.

Persson M, Simonsson M, Markkula A, Rose C, Ingvar C, Jernström H.

Br J Cancer. 2016 Jul 26;115(3):382-90. doi: 10.1038/bjc.2016.174. Epub 2016 Jun 9.

16.

CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.

Simonsson M, Veerla S, Markkula A, Rose C, Ingvar C, Jernström H.

BMC Cancer. 2016 Mar 31;16:256. doi: 10.1186/s12885-016-2284-3.

17.

Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Gustbée E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H.

BMC Clin Pathol. 2015 May 20;15:8. doi: 10.1186/s12907-015-0008-2. eCollection 2015.

18.

Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients.

Bergenfelz C, Larsson AM, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S, Jernström H, Janols H, Wullt M, Bredberg A, Rydén L, Leandersson K.

PLoS One. 2015 May 20;10(5):e0127028. doi: 10.1371/journal.pone.0127028. eCollection 2015.

19.

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, Fernö M, Ingvar C, Rose C, Bendahl PO, Rydén L, Borg Å, Gruvberger-Saal SK, Jernström H, Saal LH.

EMBO Mol Med. 2015 Aug;7(8):1034-47. doi: 10.15252/emmm.201404913.

20.

Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.

Elebro K, Borgquist S, Simonsson M, Markkula A, Jirström K, Ingvar C, Rose C, Jernström H.

Clin Cancer Res. 2015 Aug 15;21(16):3640-50. doi: 10.1158/1078-0432.CCR-14-2564. Epub 2015 Apr 22.

21.

Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer.

Rosendahl AH, Perks CM, Zeng L, Markkula A, Simonsson M, Rose C, Ingvar C, Holly JM, Jernström H.

Clin Cancer Res. 2015 Apr 15;21(8):1877-87. doi: 10.1158/1078-0432.CCR-14-1748. Epub 2015 Feb 17.

22.

History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response.

Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, Rose C, Jernström H.

Breast Cancer Res Treat. 2015 Jan;149(2):505-15. doi: 10.1007/s10549-014-3252-8. Epub 2015 Jan 4.

PMID:
25556354
23.

IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.

Markkula A, Simonsson M, Ingvar C, Rose C, Jernström H.

BMC Cancer. 2014 Oct 11;14:759. doi: 10.1186/1471-2407-14-759.

24.

Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.

Ellberg C, Jernström H, Broberg P, Borg Å, Olsson H.

Genes Chromosomes Cancer. 2015 Jan;54(1):39-50. doi: 10.1002/gcc.22217. Epub 2014 Sep 23.

PMID:
25251729
25.

Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events.

Simonsson M, Markkula A, Bendahl PO, Rose C, Ingvar C, Jernström H.

Springerplus. 2014 May 22;3:261. doi: 10.1186/2193-1801-3-261. eCollection 2014.

26.

Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort.

Elebro K, Butt S, Dorkhan M, Jernström H, Borgquist S.

Cancer Causes Control. 2014 Aug;25(8):945-57. doi: 10.1007/s10552-014-0394-2. Epub 2014 May 14.

PMID:
24825327
27.

Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H.

Int J Cancer. 2014 Oct 15;135(8):1898-910. doi: 10.1002/ijc.28831. Epub 2014 Mar 20.

28.

Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules.

Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H.

BMC Clin Pathol. 2013 Nov 4;13(1):28. doi: 10.1186/1472-6890-13-28.

29.

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.

Markkula A, Hjertberg M, Rose C, Ingvar C, Jernström H.

Acta Oncol. 2014 Feb;53(2):195-200. doi: 10.3109/0284186X.2013.840739. Epub 2013 Oct 14.

PMID:
24125101
30.

Excessive milk production during breast-feeding prior to breast cancer diagnosis is associated with increased risk for early events.

Gustbée E, Anesten C, Markkula A, Simonsson M, Rose C, Ingvar C, Jernström H.

Springerplus. 2013 Jul 3;2(1):298. doi: 10.1186/2193-1801-2-298. Print 2013 Dec.

31.

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status.

Simonsson M, Söderlind V, Henningson M, Hjertberg M, Rose C, Ingvar C, Jernström H.

Cancer Causes Control. 2013 May;24(5):929-40. doi: 10.1007/s10552-013-0169-1. Epub 2013 Feb 15.

PMID:
23412805
32.

Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms.

Borgquist S, Hjertberg M, Henningson M, Ingvar C, Rose C, Jernström H.

Breast Cancer Res Treat. 2013 Feb;137(3):849-62. doi: 10.1007/s10549-012-2367-z. Epub 2012 Dec 29.

PMID:
23274843
33.

Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort.

Markkula A, Bromée A, Henningson M, Hietala M, Ringberg A, Ingvar C, Rose C, Jernström H.

Cancer Causes Control. 2012 Aug;23(8):1307-16. doi: 10.1007/s10552-012-0008-9. Epub 2012 Jun 14.

PMID:
22695757
34.

Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort.

Markkula A, Hietala M, Henningson M, Ingvar C, Rose C, Jernström H.

Cancer Prev Res (Phila). 2012 May;5(5):735-45. doi: 10.1158/1940-6207.CAPR-11-0442. Epub 2012 Mar 8.

35.

Increased incidence of childhood, prostate and breast cancers in relatives of childhood cancer patients.

Magnusson S, Wiebe T, Kristoffersson U, Jernström H, Olsson H.

Fam Cancer. 2012 Mar;11(1):145-55. doi: 10.1007/s10689-011-9493-3.

PMID:
22120843
36.

Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients.

Lundin KB, Henningson M, Hietala M, Ingvar C, Rose C, Jernström H.

Br J Cancer. 2011 Nov 22;105(11):1676-83. doi: 10.1038/bjc.2011.441. Epub 2011 Oct 27.

37.

Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases.

Carlsson A, Wingren C, Kristensson M, Rose C, Fernö M, Olsson H, Jernström H, Ek S, Gustavsson E, Ingvar C, Ohlsson M, Peterson C, Borrebaeck CA.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14252-7. doi: 10.1073/pnas.1103125108. Epub 2011 Aug 15.

38.

Breast cancer and spider telangiectasias at diagnosis and its relation to histopathology and prognosis: a population-based study.

Ellberg C, Jernström H, Olsson H.

Breast Cancer Res Treat. 2012 Jan;131(1):177-86. doi: 10.1007/s10549-011-1707-8. Epub 2011 Aug 10.

PMID:
21830013
39.

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.

Osorio A, Milne RL, Alonso R, Pita G, Peterlongo P, Teulé A, Nathanson KL, Domchek SM, Rebbeck T, Lasa A, Konstantopoulou I, Hogervorst FB, Verhoef S, van Dooren MF, Jager A, Ausems MG, Aalfs CM, van Asperen CJ, Vreeswijk M, Waisfisz Q, Van Roozendaal CE, Ligtenberg MJ; HEBON; EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Curzon B, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Adlard J, Eccles D, Ong KR, Douglas F, Downing S, Brewer C, Walker L, Nevanlinna H, Aittomäki K, Couch FJ, Fredericksen Z, Lindor NM, Godwin A, Isaacs C, Caligo MA, Loman N, Jernström H, Barbany-Bustinza G, Liljegren A, Ehrencrona H, Stenmark-Askmalm M; Sw E-BRCA, Feliubadaló L, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Fortuzzi S, Johannsson OT, Chenevix-Trench G, Chen XC, Beesley J, Spurdle AB; kConFab, Sinilnikova OM, Healey S, McGuffog L, Antoniou AC, Brunet J, Radice P, Benítez J; CIMBA.

Br J Cancer. 2011 Apr 12;104(8):1356-61. doi: 10.1038/bjc.2011.91. Epub 2011 Mar 22.

40.

Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.

Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA; GEMO Study Collaborators, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MG, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HE, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P; SWE-BRCA, Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1032-8. doi: 10.1158/1055-9965.EPI-10-0909. Epub 2011 Mar 10.

41.

Emergency cesarean sections can be predicted by markers for stress, worry and sleep disturbances in first-time mothers.

Wangel AM, Molin J, Ostman M, Jernström H.

Acta Obstet Gynecol Scand. 2011 Mar;90(3):238-44. doi: 10.1111/j.1600-0412.2010.01056.x. Epub 2011 Feb 3.

PMID:
21306317
42.

IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families.

Rosendahl AH, Hietala M, Henningson M, Olsson H, Jernström H.

Breast Cancer Res Treat. 2011 Jun;127(3):785-94. doi: 10.1007/s10549-010-1277-1. Epub 2010 Dec 8.

PMID:
21140206
43.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B; SWE-BRCA, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M; HEBON, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L; GEMO, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay M, Vénat-Bouvet L; GEMO, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TV, Jønson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X; kConFab, Platte R, Chenevix-Trench G, Easton DF; CIMBA.

Cancer Res. 2010 Dec 1;70(23):9742-54. doi: 10.1158/0008-5472.CAN-10-1907. Epub 2010 Nov 30.

44.

IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer.

Henningson M, Hietala M, Törngren T, Olsson H, Jernström H.

Fam Cancer. 2011 Jun;10(2):173-85. doi: 10.1007/s10689-010-9404-z.

PMID:
21113804
45.

Interactions between oral contraceptive status and GSTM1 and GSTT1 deletions on insulin-like growth factor-1 (IGF-1) plasma levels in young healthy women.

Henningson MC, Hietala M, Bågeman E, Olsson H, Jernström H.

Growth Horm IGF Res. 2010 Dec;20(6):432-7. doi: 10.1016/j.ghir.2010.10.003. Epub 2010 Nov 12.

PMID:
21075030
46.

Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families.

Hietala M, Henningson M, Törngren T, Olsson H, Jernström H.

Mol Genet Metab. 2011 Jan;102(1):82-90. doi: 10.1016/j.ymgme.2010.09.006. Epub 2010 Sep 25.

PMID:
20947401
47.

Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden.

Hietala M, Henningson M, Ingvar C, Jönsson PE, Rose C, Jernström H.

Acta Oncol. 2011 Jan;50(1):134-43. doi: 10.3109/0284186X.2010.484812. Epub 2010 May 25.

PMID:
20500030
48.

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.

Jernström H, Bågeman E, Rose C, Jönsson PE, Ingvar C.

Br J Cancer. 2009 Dec 1;101(11):1817-23. doi: 10.1038/sj.bjc.6605428.

49.

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).

Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S; KConFab, Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N; OCGN, Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H, Askmalm MS, Arver B, Malmer B; SWE-BRCA, Domchek SM, Nathanson KL, Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U; HEBON, Hogervorst FB, Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A; EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK; GEMO, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Révillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D; Breast Cancer Family Registry, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TV, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benítez J; CMBA.

Br J Cancer. 2009 Dec 15;101(12):2048-54. doi: 10.1038/sj.bjc.6605416. Epub 2009 Nov 17.

50.

IGF1 and IGFBP3 polymorphisms and plasma levels in women.

Jernström H.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2794; author reply 2795. doi: 10.1158/1055-9965.EPI-09-0324. No abstract available.

Supplemental Content

Loading ...
Support Center